Managing Patients With Moderate Penetrance Genes
December 13, 2018
Dr. Susan Domchek discusses the increased understanding of moderate penetrance genes and the importance of managing patients with these genes on a case-by-case basis.
Susan M. Domchek, MD
ASCO: Treating BRCA-Positive Breast Cancer
June 3, 2014
As part of our coverage of the 2014 ASCO Annual Meeting, we discuss treatment strategies for breast cancer patients who harbor either the BRCA1 or BRCA2 mutation.
Commentary (Stopfer/Domchek): Evaluation and Management of Women With BRCA1/2 Mutations
October 1, 2005
More than a decade has passed
since the cancer predisposition
genes BRCA1 and
BRCA2 were cloned. Collectively,
these genes are responsible for virtually
all hereditary breast/ovarian cancer
families as well as a smaller subset
of hereditary site-specific breast cancer
families.[1] Their discovery helped usher
in a new age of predictive and preventive
medicine for those at risk of
breast and ovarian cancer, two of the
most common forms of cancer in women
in the United States.[2] Peshkin and
Isaacs provide an excellent summary
of cancer susceptibility due to inherited
mutations in BRCA1 and BRCA2,
including approaches to assessing personal
and family history for the likelihood
of finding these mutations, their
associated cancer risks, and options for
clinical management.
Commentary (Stopfer/Domchek): Evaluation and Management of Women With BRCA1/2 Mutations
October 1, 2005
More than a decade has passed
since the cancer predisposition
genes BRCA1 and
BRCA2 were cloned. Collectively,
these genes are responsible for virtually
all hereditary breast/ovarian cancer
families as well as a smaller subset
of hereditary site-specific breast cancer
families.[1] Their discovery helped usher
in a new age of predictive and preventive
medicine for those at risk of
breast and ovarian cancer, two of the
most common forms of cancer in women
in the United States.[2] Peshkin and
Isaacs provide an excellent summary
of cancer susceptibility due to inherited
mutations in BRCA1 and BRCA2,
including approaches to assessing personal
and family history for the likelihood
of finding these mutations, their
associated cancer risks, and options for
clinical management.
